Carregant...

Alpha-synuclein measured in cerebrospinal fluid from patients with Alzheimer’s disease, mild cognitive impairment, or healthy controls: a two year follow-up study

BACKGROUND: α-Synuclein has been proposed as a potential biomarker for Alzheimer’s disease (AD) and amnestic mild cognitive impairment (aMCI). However, results from α-synuclein measurements in cerebrospinal fluid (CSF) have been inconclusive, and to our knowledge, longitudinal studies of changes pri...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Neurol
Autors principals: Berge, Guro, Sando, Sigrid B., Albrektsen, Grethe, Lauridsen, Camilla, Møller, Ina, Grøntvedt, Gøril R., Bråthen, Geir, White, Linda R.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2016
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5031325/
https://ncbi.nlm.nih.gov/pubmed/27653987
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12883-016-0706-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!